Microfluidics News Microfluidics News

  • Acoustic Liquid Handling Mass Spectrometry Hailed as Breakthrough Technology at European Summit
    on 21st November 2017 at 12:00 am

    Labcyte Inc. today announced that its Echo® Acoustic Mass Spectrometry platform was awarded the Technology Prize during the European Laboratory Research & Innovation Group’s (ELRIG) annual Drug Discovery event in Liverpool, UK. The award was presented by ELRIG Chairman Steve Rees during the two-day international conference, which was attended by more than 1,200 delegates from pharma, biotech, academia and the drug discovery vendor community. ELRIG is a not-for-profit organization serving the life science & drug discovery communities. “We are thrilled to have received this recognition, especially since it was based on the votes of the meeting attendees,” said Mark Fischer-Colbrie, Chief Executive Officer at Labcyte. “Our goal is to continue our expansion of Acoustic-MS, with new applications, new workflows and enhanced integration into existing drug discovery processes.” Acoustic liquid dispensing, pioneered by Labcyte, uses the gentle energy of sound waves to move minute quantities of liquid with precision and accuracy. In collaboration with AstraZeneca and Waters, this technology was enhanced to generate a mass spectrometry (MS)-friendly mist of nano-droplets, in a process called Acoustic Mist Ionization (AMI). Mass spectrometers are currently used to quantify the amount of a target analyte present in screening assays, drug metabolism studies, and safety and efficacy experiments. Acoustic-MS combines the speed and low sample consumption of acoustic liquid handling with the label free nature of mass spectrometry. The system has demonstrated the ability to dramatically reduce both cost and cycle time in early drug discovery. AstraZeneca has already employed the technology’s significant capabilities, recently completing a full library screen in excess of 2 million compounds in less than six weeks. The two companies have also teamed up with pharmaceutical company GSK to further advance and test the technology in anticipation of a commercial Acoustic-MS system designed to support a broad range of biochemical and cell-based assays. About Labcyte Inc.Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® liquid handling systems uses sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 61 U.S. patents and others internationally. For more information, visit www.labcyte.com. PR Contact:Nicole LitchfieldBioscribe, Inc.415-793-6468nicole@bioscribe.com […]

  • Labcyte and FIMM Extend Personalized Medicine Collaboration
    on 8th November 2017 at 12:00 am

    Labcyte Inc. and the Institute for Molecular Medicine Finland (FIMM), a unit of the Helsinki Institute of Life Science at the University of Helsinki today announced they are extending their personalized medicine collaboration to include multiple new applications that leverage the unique capabilities of Labcyte’s Echo® Liquid Handler and Access™ Automation platform. The organizations first began collaborating in 2013 to develop new personalized medicine strategies to treat cancer based on functional cell screening. At FIMM, scientists have developed an innovative approach to cancer care that first involves testing the effects of hundreds of different drug options on the patient’s cancer cells in the lab, a process that is uniquely enabled by Labcyte’s acoustic liquid handling technology. Combined with the patient’s DNA data, this information can help doctors create a tailored treatment plan in real time. The collaboration has been expanded to include cell-based assay development and screening, such as lysate-based assays for multiplexing and standard miniaturized assays; the development of advanced cell models, such as spheroid/organoid assays, cellulose matrix for 3D cell culture, and flow cytometry assays; and integration of the Echo liquid handler in FIMM’s genomics program to include single cell genomics and population genetics workflows. “The collaboration with FIMM has been one of our most successful and productive to date,” said Mark Fischer-Colbrie, Chief Executive Officer at Labcyte. “We have been working together for the past four years to break new ground in personalized medicine and functional cell screening, and this work is being modeled now in many centers around the world. The team at FIMM have enabled patients to achieve remission and identified drugs and drug combinations that can be used more broadly. We are looking forward to working on these new projects.” “FIMM’s Individualized Systems Medicine in Cancer program has greatly benefited from Labcyte’s acoustic liquid handling technology,” said Janna Saarela, Research Director at FIMM and the Head of the FIMM Technology Centre. “Our collaboration has been essential for the successful drug sensitivity testing assays we have set up. Now we aim to expand the use of Labcyte’s equipment to our genomic workflows, enabling us to miniaturize assays, make complex liquid handling processes simple, and explore the use of acoustic liquid handling for biobanked DNA samples.” For more information, please visit www.labcyte.com/personalized-medicine. About Labcyte Inc.Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® liquid handling systems uses sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 61 U.S. patents and others internationally. For more information, visit www.labcyte.com. About FIMMInstitute for Molecular Medicine Finland (FIMM) is an international research institute in Helsinki focusing on human genomics and personalized medicine. In the beginning of 2017 FIMM joined the University of Helsinki’s new life science research center, Helsinki Institute of Life Science HiLIFE, as an operational unit. FIMM integrates molecular medicine research, technology center and biobanking infrastructures under one roof, promoting translational research in grand challenge projects, specifically, the impact of genome information from the Finnish population in personalized health and medicine, individualized cancer medicine, and digital diagnostics for precision medicine. FIMM is part of the Nordic EMBL Partnership in Molecular Medicine and the EU-LIFE alliance. For more information, visit www.fimm.fl/en/. PR Contact:Nicole LitchfieldBioscribe, Inc.415-793-6468nicole@bioscribe.com PR Contact for FIMM:Mari KaunistoInstitute for Molecular Medicine Finland (FIMM)HiLIFE, University of Helsinkimari.kaunisto@helsinki.f […]

  • Microfluidics on Glass Award sponsored by IMT Masken und Teilungen AG
    on 19th October 2017 at 9:12 am

    The 21st International Conference on Miniaturized Systems for Chemistry and Life Sciences (MicroTAS 2017) October 22-26, 2017 Microfluidics on Glass Award sponsored by IMT Masken und Teilungen AG The MicroTAS 2017 Conference is pleased to announce the Microfluidics on Glass Award, sponsored by IMT Masken und Teilungen AG of Switzerland, to recognize an individual who has demonstrated exceptional technical advancement and innovation in the field of microfluidics or nanofluidics by using glass in a key aspect of their device. […]

  • GSK, AstraZeneca and Labcyte Form Alliance to Develop Acoustic Mass Spectrometry
    on 20th September 2017 at 12:00 am

    Labcyte Inc. today announced that GSK has joined its consortium with AstraZeneca to combine acoustic liquid dispensing technology from Labcyte with Mass Spectrometry (MS) for use in high throughput small molecule screening and other drug discovery applications. Acoustic liquid dispensing, pioneered by Labcyte, uses the gentle energy of sound waves to move minute quantities of liquid with precision and accuracy. It has been enhanced to generate an MS-friendly mist of nano-droplets in a process called Acoustic Mist Ionization (AMI). Mass spectrometers are currently used to quantify the amount of drug substance present in screening assays, drug metabolism studies, and safety and efficacy experiments. The use of MS through AMI in high throughput applications has the potential to reduce both cost and cycle time in early drug discovery. “Labcyte’s standard acoustic liquid handling has already been deployed across many areas of life science research and drug development as the result of its many benefits,” said Mark Fischer-Colbrie, Chief Executive Officer at Labcyte. “Our goal is to continue that expansion with Acoustic-MS. We have made significant progress in collaboration with AstraZeneca over the past four years with great results. This new consortium will help validate new applications and optimize the Acoustic-MS technology for both creating new workflows as well as for fitting into existing drug discovery processes.” With the addition of GSK, the companies have formed a consortium to advance the development of Acoustic-MS for high-throughput chemistry analysis, and biochemical and cell-based assays supporting a range of drug targets. Both pharmaceutical companies will work with multiple prototype instruments – applying the technology to high-priority assays – and will share their findings with other members of the consortium. Labcyte plans to launch a commercial Acoustic-MS system designed to support a broad range of assays. AstraZeneca has demonstrated the technology’s significant capabilities to conduct biochemical screening applications at rates up to three samples per second. For example, AZ recently completed a full library screen of 2.7 million compounds in less than six weeks using this approach. AstraZeneca’s Jonathan Wingfield, Principal Scientist, Discovery Sciences, Innovative Medicines AZ, is excited about these great advancements. “We have proven that Acoustic-MS technology works, and generates vastly reduced assay development times, improved cost savings and fewer false positives. The addition of GSK provides the opportunity to expand the development of this technology and reinforces AstraZeneca’s commitment to open innovation.” Melanie Leveridge, Director, Screening, Profiling and Mechanistic Biology at GSK, commented: “We value innovation and collaborative development, and are excited to be working with Labcyte and AstraZeneca to further develop Acoustic-MS for high throughput screening applications, as well as exploring new opportunities for this technology in high throughput chemistry analysis.” About Labcyte Inc.Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® liquid handling systems uses sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 60 U.S. patents and others internationally. For more information, visit www.labcyte.com. PR Contact:Nicole LitchfieldBioscribe, Inc.415-793-6468nicole@bioscribe.com […]

  • Labcyte Introduces New 384-Well Low Dead Volume Microplate for Echo® 525 Liquid Handlers
    on 14th September 2017 at 12:00 am

    Labcyte Inc., a company revolutionizing life science research with its patented acoustic liquid handling technology, today announced the release of a new 384-well low dead volume microplate for its Echo® 525 Liquid Handlers. The new Echo® Qualified 384 LDV Plus Microplate reduces the amount of sample or reagent required in a well for transfer by 75% or more. Labcyte’s Echo 525 Liquid Handlers use focused sound energy to dispense precisely sized 25nL droplets of samples or reagents from microplate to microplate without the contact of tips or nozzles. Larger volume transfers are achieved by transferring several hundred droplets per second. This reduces costs by allowing miniaturization and leads to improved results by eliminating the contamination risks associated with tips. The speed at which Echo systems transfer fluid from any well on a microplate to any well on another microplate has driven its adoption for pooling in synthetic biology and genomics applications where DNA oligos, sequencing libraries and PCR primers are pooled in random combinations. With the ability to miniaturize reaction volumes while improving experimental outcomes, Echo system users in academic institutions as well as industrial biotechnology and pharmaceutical companies experience immediate improvements in efficiency and productivity. “The Echo 525 Liquid Handler has proven to dramatically reduce the costs and time of sample preparation for core labs, DNA foundries and synthetic biology organizations that rely on automated liquid handling to prepare samples for a wide range of experiments,” said Chris Grimley, Labcyte’s Vice President of Marketing. “Our new plate with a lower dead volume requirement will give customers higher cost savings with every experiment. This is especially helpful for customers performing miniaturized reactions for next-generation sequencing library preparation and PCR assays.” About Labcyte Inc.Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo Liquid Handlers use sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical industry, as well as by biotechnology companies, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 60 U.S. patents and others internationally. For more information, visit www.labcyte.com. PR Contact:Nicole LitchfieldBioscribe, Inc.415-793-6468nicole@bioscribe.com […]